Recombinant Human Siglec-2/CD22 Protein, Atto 647N Conjugate
Recombinant Human Siglec-2/CD22 Protein, Atto 647N Conjugate Summary
Learn more about FluorokinesTM Fluorescent-Labeled ProteinsProduct Specifications
Measured by flow cytometry for its ability to bind anti-Human Siglec-2/CD22 Monoclonal Antibody conjugated fluorescent beads.
| Human Siglec-2/CD22 (Asp20-Arg687) Accession # CAA42006.1 | DIEGRMD | Human IgG1 (Pro100-Lys330) |
| N-terminus | C-terminus | |
Analysis
Excitation Wavelength: 647 nm
Emission Wavelenght: 667 nm
Product Datasheets
ATM1968
| Formulation | Supplied as a 0.2 μm filtered solution in PBS with BSA as a carrier protein. |
| Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Protect from light. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
Fluorescent beads conjugated to anti-Human Siglec 2/CD22 Monoclonal Antibody (MAB1968) were stained with (A) Recombinant Human Siglec 2/CD22 Protein, Atto 647N Conjugate (Catalog # ATM1968) or (B) unstained.
View Larger
2 μg/lane of Recombinant Human Siglec-2/CD22 Protein, Atto 647N Conjugate (Catalog # ATM1968) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 114-126 kDa and 228-252 kDa, respectively.
Reconstitution Calculator
Background: Siglec-2/CD22
Siglecs (sialic acid binding Ig-like lectins) are I-type (Ig-type) lectins belonging to the Ig superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains (1, 2). Eleven human Siglecs have been cloned and characterized. They are sialoadhesin/CD169/Siglec-1, CD22/Siglec-2, CD33/Siglec-3, Myelin-Associated Glycoprotein (MAG/Siglec-4a) and the identified Siglecs 5 to 11 (1 ‑ 3). To date, no Siglec has been shown to recognize any cell surface ligand other than sialic acid, suggesting that interactions with glycans containing this carbohydrate are important in mediating the biological functions of Siglecs. Human Siglec-2, also known as B‑cell antigen CD22 or B‑lymphocyte cell adhesion molecule (BL-CAM), is a B‑cell restricted glycoprotein that is expressed in the cytoplasm of progenitor B and pre-B cells and on the surface of mature B cells. Two distinct human Siglec-2/CD22 cDNAs that arise from differential RNA processing of the same gene have been isolated. The predominant Siglec-2/CD22 beta encodes an 847 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-terminal Ig-like V-type domain, six Ig-like C2-type domains, a transmembrane region and a cytoplasmic tail with 4 immunoreceptor tyrosine-based inhibition motifs (ITIMs) (4). The variant Siglec-2/CD22 alpha encodes a 647 aa polypeptide missing two Ig-like C2-type domains and has a truncated (23 aa) cytoplasmic tail (5). Siglec-2/CD22 is an adhesion molecule that preferentially binds alpha 2,6- linked sialic acid on the same (cis) or adjacent (trans) cells. Interaction of CD22 with trans ligands on opposing cells was found to be favored over the binding of ligands in cis (9). Besides its role as an adhesion molecule, Siglec-2/CD22 is a coreceptor that physically interacts with B‑cell receptor (BCR) and is rapidly phosphorylated upon BCR ligation. It negatively regulates BCR signals by recruiting tyrosine phosphatase SHP-1 to its ITIMs. Phosphorylated Siglec-2/CD22 can also interact with other intracellular effector proteins such as Syk, PLC gamma, PI3 kinase and Grb-2, suggesting it may play a role in positive signaling (2, 7, 8).
- Crocker, P.R. and A. Varki (2001) Trends Immunol. 22:337.
- Crocker, P.R. and A. Varki (2001) Immunology 103:137.
- Angata, T. et al. (2002) J. Biol. Chem. 277:24466.
- Wilson, G.L et al. (1991) J. Exp. Med. 173:137.
- Stamenkovic, I. and B. Seed (1990) Nature 345:74.
- Kelm, S. et al. (1994) Current Bio. 4:965.
- Ravetch, J.V. and L.L. Lanier (2000) Science 290:84.
- Wienands, Y.J. et al. (1999) J. Biol. Chem. 274:18769.
- Collins, B.E. et al. (2004) Proc. Natl. Acad. Sci. 101:6104.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human Siglec-2/CD22 Protein, Atto 647N Conjugate
There are currently no reviews for this product. Be the first to review Recombinant Human Siglec-2/CD22 Protein, Atto 647N Conjugate and earn rewards!
Have you used Recombinant Human Siglec-2/CD22 Protein, Atto 647N Conjugate?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
